✦ LIBER ✦

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

✍ Scribed by Laurence J. C. van Warmerdam, Jaap Verweij…

Book ID: 120777446
Publisher: Springer
Year: 1995
Tongue: English
Weight: 869 KB
Volume: 35
Category: Article
ISSN: 0344-5704
DOI: 10.1007/BF00686554

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of the

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

✍ Kerbusch, T; Groenewegen, G; Mathôt, R A A; Herben, V M M; ten Bokkel Huinink, W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I and pharmacologic study of diflo

Phase I and pharmacologic study of diflomotecan (BN80915) administered intravenously daily for 5 consecutive days every 3 weeks in patients with solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 144 KB

A Phase II study of intravenous exatecan

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi

A phase II study of intravenous exatecan

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

✍ Claire F. Verschraegen; Andrzej P. Kudelka; Wei Hu; Monique Vincent; John J. Kay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 736 KB

A phase II study of topotecan administer

A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma

✍ Kudelka, A.; Edwards, C.; Freedman, R.; Wallin, B.; Hord, M.; Howell, E.; Harper 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Safety, pharmacokinetics and pharmacodyn

Safety, pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days

✍ Wood, Chester C; Yong, Chan-Loi; Madwed, Jeffrey B; Gupta, Abhya 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 150 KB